Teva launches Adasuve in the U.S.; Sanofi files heart-drug suit against Actavis;

@FiercePharma: Best-read over the weekend: Pradaxa, Xarelto makers dispute purported Eliquis safety edge. Piece | Follow @FiercePharma

@TracyStaton: The graph's the thing: Takeda admits to 'inappropriate' drug advertising in Japan. News (sub. req.) | Follow @TracyStaton

@EricPFierce: WSJ says Pfizer angling for OTC Lipitor. That will get generic drugmakers' notice. Story | Follow @EricPFierce

@CarlyHFierce: Teva's new Copaxone formula could be a hard sell with payers. Article | Follow @CarlyHFierce

> Teva ($TEVA) has launched Adasuve, an inhaled medicine to treat agitation in patients with schizophrenia or bipolar disorder, in the U.S. Report | Release

> Sanofi ($SNY) is suing Actavis ($ACT) over allegedly infringing patents on its heart drug Multaq. Report | Release

> AstraZeneca ($AZN) has won U.S. approval for a pen-injector version of once-weekly diabetes med Bydureon. News

> The FDA will increase access to morning-after pill generics. More

> The chronically ill are still facing high drug costs in the U.S. despite the ban on discriminatory health insurance practices against the sick. Story

Medical Device News

@FierceMedDev: How to gain new stent sales in a sluggish market: bulk discount deals. Story | Follow @FierceMedDev

@MarkHFierce: For Covidien, a ventilation system wins a CE mark after other product setbacks in the space. More | Follow @MarkHFierce

@MichaelGFierce: New manufacturing technique offers tailored delivery nanoparticles made of iron, silver and silicon. Article from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: White noise sleep machines at full volume could cause hearing damage in infants, say researchers. News | Follow @EmilyWFierce

> Abbott and Medtronic are sharing a bulk discount deal to sell stents at 135 hospitals. More

> GE Ventures pours cash into RainDance's $16.5M Series E extension. Story

> BSD bets on new ablation device sales growth in its ongoing Terumo deal. More

Biotech News

@FierceBiotech: GlaxoSmithKline hits the brakes on an anti-inflammatory drug from Galapagos. News | Follow @FierceBiotech

@JohnCFierce: Remember that big Gilead bet on Pharmasset? It paid off and made John Martin a billionaire. Item | Follow @JohnCFierce

@DamianFierce: India's Lupin queues up for a share of the biosimilar boom. Story | Follow @DamianFierce

@EmilyMFierce: Experimental supplement extends lifespan, stops metabolic disease in mice. Article from FierceBiotechResearch | Follow @EmilyMFierce

> Roche racks up another PhIII setback as MetMab flops against lung cancer. News

> Scientific insights into brain chemistry trigger drug trials for Down syndrome. Story

> Investigators ID a rare antibody that may offer a key to elusive HIV vaccine. Research

CRO News

> InVentiv amps up its biosimilar efforts with latest deal. Story

> Report: VC giant Sequoia unloading $50M stake in India's GVK. News

> Quintiles touts its talent as cash rolls in. Article

> Cardialysis taps AG Mednet to handle an ocean of trial data. Story

> MPI's imaging team-up snags a cyclotron as it preps for opening day. Story

> Charles River looks to Exostar for cloud-based data platform. Brief

Biotech IT News

> Google joins genomics alliance as it prepares industry-focused cloud services. News

> Novartis' pitch to join trial data sharing bandwagon gets frosty reception. Story

> U.K. begins trying to rebuild trust in patient database after months of 'confusion, suspicion and anxiety.' Article

> FDA defends itself against accusations its email snooping broke whistleblower laws. Story

> George Washington University to trial 40-Gbps genomics data transfers with NIH. Article

> NIH adds genetic data from Kaiser, UCSF to online resource. Brief

And Finally... Public health officials are eyeing a debilitating mosquito-borne virus that could soon break out across large parts of the Americas. More (sub. req.)

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

AstraZeneca has signed into the EU’s first finalized COVID-19 vaccine supply agreement.  

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.